RegulatoryGuideline · draft
Forms FDA 3542a and FDA 3542: Questions and Answers
🇺🇸 FDA · Mon 15 Jun 2026
The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry titled "Forms FDA 3542a and FDA 3542: Questions and Answers." This draft guidance is intended to answer commonly asked questions regarding Forms FDA 3542a and FDA 3542, and to assist applicants in preparing and submitting these forms to FDA.
Official guideline text: FDA ↗
Brief written by VigiEye from the company's press release. Claims are the company's own. AI-assisted; check the source before acting.
More Regulatory
All →
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
BeyondSpring, Inc. · Fri 13 Nov 2026
Imricor starts US launch of NorthStar iMR system after paediatric FDA clearances
🇺🇸 Imricor Medical Systems, Inc. · Fri 13 Nov 2026
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
🇺🇸 Beyond Air, Inc. (XAIR) · Fri 13 Nov 2026
FDA sets 10 March 2027 goal date for Intellia's one-time hereditary angioedema gene-editing therapy
🇺🇸 Intellia Therapeutics, Inc. (NTLA) · Fri 13 Nov 2026
BeyondSpring wins FDA Fast Track for plinabulin plus docetaxel in post-immunotherapy NSCLC
🇺🇸 BeyondSpring Inc. (BYSI) · Fri 13 Nov 2026
FDA grants NeOnc Type B meeting on accelerated approval path for intranasal NEO100
🇺🇸 Neonc Technologies Holdings, Inc. (NTHI) · Fri 13 Nov 2026